Condition

Metastatic Prostate Small Cell Carcinoma

ClinicalTrials.gov condition label

Clinical trials2

Recruiting0

Common interventions7

Lead sponsors shown2

Clinical trials

2 shown

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerNCT04471974 · 2021-01-26

ACTIVE_NOT_RECRUITING

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate CancerNCT04592237 · 2020-12-29

ACTIVE_NOT_RECRUITING

Common interventions

BET Bromodomain Inhibitor ZEN-3694DRUG1CabazitaxelDRUG1CarboplatinDRUG1CetrelimabBIOLOGICAL1EnzalutamideDRUG1NiraparibDRUG1PembrolizumabBIOLOGICAL1

Leading sponsors

M.D. Anderson Cancer Center1Rahul Aggarwal1

Trial status mix

ACTIVE_NOT_RECRUITING2

Phase mix

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.